search
Back to results

Pilot Study to Determine Percent Tissue Perfusion and Cellular Viability Using SPY Imaging

Primary Purpose

Peripheral Vascular Disease

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
SPY Imaging, ICG dye (0.2 - 0.5 mg/kg)
SPY Imaging
Sponsored by
Georgetown University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Peripheral Vascular Disease

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subject is at least 18 years or older.
  • Subject has PVD demonstrated by angiogram.
  • Subject is undergoing the first amputation/debridement after vascular intervention, if intervention is/was warranted.
  • Subject has had a vascular consult and/or intervention.
  • Subject must sign an IRB approved informed consent.
  • Subject is willing and able to complete required follow up.

Exclusion Criteria:

  • Subject has no evidence of PVD
  • Subject's wound presents with a malignancy in the wound bed.
  • Subject has liver disease (Previously diagnosed with liver disease or elevated AST, ALT, Alk Phos, or Bilirubin labs within 30 days of procedure).
  • Subject has a disorder or situation that the investigator believes will interfere with study compliance.

Sites / Locations

  • Georgetown University Medical Center; Center for Wound Healing

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

No Intervention

Experimental

Experimental

Arm Label

SPY Imaging

No SPY Imaging

Validation Against Angiogram

Establishing Normal Values

Arm Description

SPY Imaging Prior to Amputation or Debridements (50 participants)

Amputation or Debridements as Standard of Care (50 participants)

Patients who are scheduled to undergo an angiogram will also receive ICG angiography (SPY). This will occur at specific time points: 1.) before the angiogram/intervention is performed 2.) immediately after the angiogram/intervention is performed 3.) 5-7 days after angiogram/intervention 4.) 21-30 days after angiogram/intervention. (30 participants)

To establish baseline lower extremity perfusion in non-PVD patients. Patients requiring an angiogram for other vascular processes unrelated to the lower extremity will be recruited into this study. ICG angiography (SPY) of the lower extremity will be performed at the time of the angiogram. (30 Participants)

Outcomes

Primary Outcome Measures

Determination of percent cellular viability
Determine percent cellular viability (vs. apoptotic/dead) of cells at demarcation line
Rate of infection, dehiscence and re-amputation
Rate of infection, dehiscence and re-amputation in patients undergoing SPY imaging
Number of debridements, revisional surgeries and days of stay in hospital
The endpoint for evaluation will be the number of revisional surgeries and number of days of stay in hospital within 20 weeks of the first procedure.

Secondary Outcome Measures

Full Information

First Posted
January 27, 2012
Last Updated
March 9, 2020
Sponsor
Georgetown University
search

1. Study Identification

Unique Protocol Identification Number
NCT01522495
Brief Title
Pilot Study to Determine Percent Tissue Perfusion and Cellular Viability Using SPY Imaging
Official Title
Pilot Study for: Eye vs. Spy - A Prospective, Randomized Study Evaluating Patient Outcomes With the Use of SPY Imaging During Amputations or Debridements
Study Type
Interventional

2. Study Status

Record Verification Date
March 2020
Overall Recruitment Status
Completed
Study Start Date
April 2013 (undefined)
Primary Completion Date
December 2019 (Actual)
Study Completion Date
December 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Georgetown University

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Little is known about chronic wound microenvironments, especially in peripheral vascular disease (PVD) and diabetic patients. At the demarcation line, the percentage of viable cells and tissue is unclear. A means to determine cell viability, particularly discerning an apoptotic or necrotic cell pathway would indicate where the line of demarcation should be drawn. The information generated would better predict clinical outcome using SPY Imaging. Cellular studies are needed to successfully confirm a clear line of demarcation to eliminate surgeon subjectivity.
Detailed Description
Peripheral arterial disease (PAD), like other more central macrovascular diseases, is common in diabetes. PAD can lead to critical limb ischemia, either alone or when combined with an injury like a foot ulcer. The diabetic foot ulceration requires adequate circulation to heal; if the circulation is impaired such that the tissue oxygen demand exceeds supply, critical limb ischemia ensues, placing the limb at risk. Most often, patients with critical limb ischemia, undergo multiple debridements in the operating room as well as vascular procedures, prior to reaching a viable level of amputation. This increases the patients' co-morbidities from repetitive exposure to anesthesia. Each debridement may be removing viable tissue and decreasing the length of the eventual amputation. Additionally, intraoperatively, the viability of the skin edges is a subjective assessment based on the surgeon's experience. That judgement can be inaccurate in 10-20% of cases and lad to reoperation. With the use of the SPY imaging system, a better assessment of not only macrovascularity, but also microvascularity of the tissues is able to be evaluated objectively. This helps identify the tissues that are underperfused. The investigators are unaware of any literature evaluating the use of SPY imaging in the lower extremities intraoperatively during amputations or debridements. There are many studies published for the use of this technology during ophthalmic procedures , cerebral aneurismal repair, cardiac surgery and breast reconstruction. In cardiac surgery, the use of ICG based imaging has proven to be helpful in assessing the quality of bypass grafts and eliminating the need for radiography or catheter insertion (Reuthebuch et al., 2004). In ophthalmic procedures, ICG angiography has been fundamental in identifying many microvascular pathologies (Slakter, Yannuzzi, Guyer, Sorenson, & Orlock, 1995). Furthermore, neurosurgeons have found that the use of ICG angiography is far more superior than DS angiography in identifying small vessels . As it has already been proven to be a good adjunct intraoperatively to visualize microvasculature, the investigators would like to apply this to the lower extremities. Identifying underperfused tissues intraoperatively can help the surgeon objectively decide an appropriate level of amputation/debridement to effectively minimize the number of revisional surgeries. Also, there are no studies that comprehensively evaluate and compare the effectiveness of other modalities that also attempt to assess vascularity with the SPY imaging system. The information gained could be pivotal and help to gain more insight in patients with difficult to heal wounds, especially in the presence of PVD.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Vascular Disease

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
31 (Actual)

8. Arms, Groups, and Interventions

Arm Title
SPY Imaging
Arm Type
Experimental
Arm Description
SPY Imaging Prior to Amputation or Debridements (50 participants)
Arm Title
No SPY Imaging
Arm Type
No Intervention
Arm Description
Amputation or Debridements as Standard of Care (50 participants)
Arm Title
Validation Against Angiogram
Arm Type
Experimental
Arm Description
Patients who are scheduled to undergo an angiogram will also receive ICG angiography (SPY). This will occur at specific time points: 1.) before the angiogram/intervention is performed 2.) immediately after the angiogram/intervention is performed 3.) 5-7 days after angiogram/intervention 4.) 21-30 days after angiogram/intervention. (30 participants)
Arm Title
Establishing Normal Values
Arm Type
Experimental
Arm Description
To establish baseline lower extremity perfusion in non-PVD patients. Patients requiring an angiogram for other vascular processes unrelated to the lower extremity will be recruited into this study. ICG angiography (SPY) of the lower extremity will be performed at the time of the angiogram. (30 Participants)
Intervention Type
Device
Intervention Name(s)
SPY Imaging, ICG dye (0.2 - 0.5 mg/kg)
Other Intervention Name(s)
Indocyanine Green, IC-GREEN
Intervention Description
Intravenous(1X) in conjunction with SPY Imaging (1 arm)
Intervention Type
Device
Intervention Name(s)
SPY Imaging
Intervention Description
SPY Imaging to assess tissue perfusion
Primary Outcome Measure Information:
Title
Determination of percent cellular viability
Description
Determine percent cellular viability (vs. apoptotic/dead) of cells at demarcation line
Time Frame
6 weeks
Title
Rate of infection, dehiscence and re-amputation
Description
Rate of infection, dehiscence and re-amputation in patients undergoing SPY imaging
Time Frame
20 weeks
Title
Number of debridements, revisional surgeries and days of stay in hospital
Description
The endpoint for evaluation will be the number of revisional surgeries and number of days of stay in hospital within 20 weeks of the first procedure.
Time Frame
20 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subject is at least 18 years or older. Subject has PVD demonstrated by angiogram. Subject is undergoing the first amputation/debridement after vascular intervention, if intervention is/was warranted. Subject has had a vascular consult and/or intervention. Subject must sign an IRB approved informed consent. Subject is willing and able to complete required follow up. Exclusion Criteria: Subject has no evidence of PVD Subject's wound presents with a malignancy in the wound bed. Subject has liver disease (Previously diagnosed with liver disease or elevated AST, ALT, Alk Phos, or Bilirubin labs within 30 days of procedure). Subject has a disorder or situation that the investigator believes will interfere with study compliance.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christopher E Attinger, MD
Organizational Affiliation
Georgetown University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Georgetown University Medical Center; Center for Wound Healing
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20007
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Pilot Study to Determine Percent Tissue Perfusion and Cellular Viability Using SPY Imaging

We'll reach out to this number within 24 hrs